or
forgot password

A Phase 3 Trial of LY900003 Plus Gemcitabine and Cisplatin Versus Gemcitabine and Cisplatin in Patients With Advanced, Previously Untreated Non-Small Cell Lung Cancer


Phase 3
18 Years
N/A
Not Enrolling
Both
Carcinoma, Non-Small-Cell Lung

Thank you

Trial Information

A Phase 3 Trial of LY900003 Plus Gemcitabine and Cisplatin Versus Gemcitabine and Cisplatin in Patients With Advanced, Previously Untreated Non-Small Cell Lung Cancer


Inclusion Criteria:



1. Stage IIIB or IV non-small lung cancer

2. Able to visit the doctor's office

3. At least 18 years of age

4. Adequate kidney, adrenal, and liver function

Exclusion Criteria:

1. Prior chemotherapy or biologic therapy for NSCLC

2. Central nervous system tumors

3. Pregnant or breastfeeding

Type of Study:

Interventional

Study Design:

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Authority:

United States: Food and Drug Administration

Study ID:

6428

NCT ID:

NCT00034268

Start Date:

March 2002

Completion Date:

Related Keywords:

  • Carcinoma, Non-Small-Cell Lung
  • non-small cell lung cancer
  • Stage IIIB or IV non-small cell lung cancer (NSCLC)
  • Carcinoma
  • Carcinoma, Non-Small-Cell Lung
  • Lung Neoplasms

Name

Location
Alexandria, Minnesota  56308
Albany, Georgia  31701
Fountain Valley, California  92708
Albany, New York  12208
Austin, Texas  78705
Flint, Michigan  48532
McLean, Virginia  22101
Little Rock, Arkansas  72205-7199
Metairie, Louisiana  70006
Denver, Colorado  
Baltimore, Maryland  21287
Milwaukee, Wisconsin  
Wilmington, Delaware  
Indianapolis, Indiana